(Circulation. 1995;92:106-113.)
© 1995 American Heart Association, Inc.
Articles |
Role of Endogenous Endothelin-1 in Experimental Renal Hypertension in Dogs
From the Divisions of Endocrinology and Internal Medicine (J.D., L.G.), University Hospital UCL of Mont-Godinne, Yvoir, Belgium; Departments of Physiology and Cardiology (L.S., W.H., H.V.M., H.P.) and the Unit of Diabetology and Nutrition (P.S., J.-M.K.), University of Louvain, Brussels, Belgium; and the Pharma Division (J.-P.C.), Preclinical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Correspondence to Julian Donckier, MD, PhD, Endocrinology and Internal Medicine, University Hospital of Mont-Godinne, 5530 Yvoir, Belgium.
Background Endothelin-1, a vasoconstrictive peptide released by endothelium, may be involved in the pathophysiology of hypertension. The goal of the present study was to evaluate the role of endogenous endothelin-1 in renal hypertension in dogs. The model of hypertension consisted of silk tissue wrapping of the left kidney, which produced hypertension associated with perinephritis after 6 to 8 weeks.
Methods and Results Thirty-two anesthetized open chest dogs were studied randomly: 8 dogs with perinephritic hypertension received the nonpeptidic ETA-ETB receptor antagonist bosentan (group 1); 8 other hypertensive dogs received the vehicle solution (group 2); 8 healthy dogs received bosentan (group 3); and 8 healthy dogs received the vehicle solution (group 4). Bosentan was injected as an intravenous bolus (3 mg/kg) followed by a 1-hour infusion at a rate of 7 mg · kg-1 · h-1. In hypertensive dogs, bosentan produced a similar decrease (P=.0001) of both left ventricular systolic and mean aortic pressures, which averaged 38 mm Hg (-22% and -24%, respectively). These parameters remained unchanged with the vehicle solution. Left ventricular end-diastolic and left atrial pressures also declined significantly with bosentan (P=.0005 and P<.05, respectively). Left ventricular lengths tended to decrease. The other cardiovascular parameters (heart rate, peak [+]dP/dt, time constant of relaxation, and coronary vascular resistance) did not change significantly. In healthy dogs, bosentan decreased mean aortic pressure by 19 mm Hg (P=.004). Vehicle solution had no effect. Plasma endothelin-1 levels, similar under basal conditions in healthy and hypertensive dogs, increased 30-fold with bosentan (P=.0001).
Conclusions Specific endothelin-1 receptor antagonism markedly lowers blood pressure in experimental hypertension but is less effective on blood pressure of healthy animals. This suggests that endothelin-1 plays a role in the pathophysiology of hypertension but contributes to a lesser extent to the maintenance of normal blood pressure. This role of endothelin-1 is unrelated to its plasma levels. The increase of plasma endothelin-1 with bosentan, due either to a displacement of endothelin-1 from its receptor or to a feedback mechanism, does not prevent this blood pressure reduction.
Key Words: endothelin • hypertension • kidneys
This article has been cited by other articles:
 |
|
 |
|
  C. Y.T. Hart, D. M. Meyer, H. D. Tazelaar, J. P. Grande, J. C. Burnett Jr, P. R. Housmans, and M. M. Redfield Load Versus Humoral Activation in the Genesis of Early Hypertensive Heart Disease Circulation, July 10, 2001; 104(2): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Reinhart, L. C. Preusser, T. J. Opgenorth, C. D. Wegner, and B. F. Cox Endothelin and ETA receptors in long-term arterial pressure homeostasis in conscious nonhuman primates Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2000; 279(5): R1701 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Berthold, K. Munter, A. Just, H. R. Kirchheim, and H. Ehmke Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog Am J Physiol Renal Physiol, March 1, 1999; 276(3): F417 - F424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cardillo, C. M. Kilcoyne, M. Waclawiw, R. O. Cannon III, and J. A. Panza Role of Endothelin in the Increased Vascular Tone of Patients With Essential Hypertension Hypertension, February 1, 1999; 33(2): 753 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Borgeson, J. A. Grantham, E. E. Williamson, A. Luchner, M. M. Redfield, T. J. Opgenorth, and J. C. Burnett Jr Chronic Oral Endothelin Type A Receptor Antagonism in Experimental Heart Failure Hypertension, March 1, 1998; 31(3): 766 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hayashida, J. Donckier, H. Van Mechelen, A. A. Charlier, and H. Pouleur Load-sensitive diastolic relaxation in hypertrophied left ventricles Am J Physiol Heart Circ Physiol, February 1, 1998; 274(2): H609 - H615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Donckier, P.-E. Massart, D. Hodeige, H. Van Mechelen, J.-P. Clozel, O. Laloux, J.-M. Ketelslegers, A. A. Charlier, and G. R. Heyndrickx Additional Hypotensive Effect of Endothelin-1 Receptor Antagonism in Hypertensive Dogs Under Angiotensin-Converting Enzyme Inhibition Circulation, August 19, 1997; 96(4): 1250 - 1256. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Hayashida, J. Donckier, H. Van Mechelen, A. A. Charlier, and H. Pouleur Diastolic properties in canine hypertensive left ventricular hypertrophy: Effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade Cardiovasc Res, January 1, 1997; 33(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupuis, C. A. Goresky, and A. Fournier Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors J Appl Physiol, October 1, 1996; 81(4): 1510 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, D. J. Stewart, P. Cernacek, and G. Gosselin Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1 Circulation, October 1, 1996; 94(7): 1578 - 1584. [Abstract] [Full Text]
|
|